Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo (MASI) reported earnings 30 days ago. What's next for the stock?

Masimo (MASI) Down 1.2% Since Last Earnings Report: Can It Rebound?

PARIS--(BUSINESS WIRE)--MDoloris Medical Systems, a leader in the field of objective pain monitoring during anesthesia, announces today the regulatory clearance and marketing approval of its HFVI MOC-9, High Frequency Variability Index monitor, in Japan. MDoloris' HFVI MOC-9 Technology is the first monitoring solution for patients going through analgosedation and anesthesia in Japan. The HFVI MOC-9 is a solution developed by MDoloris for Masimo (NASDAQ: MASI) for integration into its Root patie

MDoloris Medical Systems Announces the Regulatory Clearance and the Upcoming Launch of its Analgesia Nociception Index Platform in Japan with Heiwa Bussan

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Piper Sandler 33rd Annual Healthcare Conference on Tuesday, November 30, 2021 at 2:00 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produce

Masimo to Present in Piper Sandler 33rd Annual Healthcare Conference

The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.

Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A study found that general anesthesia guided by a combination of Masimo SedLine® processed EEG parameters PSi and DSA reduced postoperative delirium.

New Study Finds That Use of Masimo SedLine® PSi and DSA May Significantly Reduce Postoperative Delirium

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 4:00 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wi

Masimo to Present in Stifel 2021 Virtual Healthcare Conference

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study used a multimodal brain monitoring algorithm based on Masimo Root® measurements to manage anesthesia during surgery in elderly patients.

Masimo Root® with a Multimodal Brain Monitoring Algorithm May Improve Postoperative Neurocognition in Elderly Patients

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo announced Dual SET® Pulse Oximetry with the CE marking and launch of the SET® Module and Eve™ CCHD Newborn Screening Application for Root®.

Masimo Launches Dual SET® Pulse Oximetry

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.

Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up

Masimo Corporation (MASI) CEO Joe Kiani on Q3 2021 Results - Earnings Call Transcript

Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 3.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Beats Q3 Earnings and Revenue Estimates

Masimo (NASDAQ:MASI) reported its Q3 earnings results on Tuesday, October 26, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Recap: Masimo Q3 Earnings

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the third quarter of 2021, ended October 2, 2021. Third Quarter 2021 Results Product revenue was $307.4 million, which represents 10.5% reported growth and 10.1% growth on a constant currency basis, compared to $278.1 million in the third quarter of 2020. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 74,600 in the third quarter of 2

Masimo Reports Third Quarter 2021 Financial Results

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo (MASI) Earnings Expected to Grow: Should You Buy?

IRVINE, Calif.--(BUSINESS WIRE)--An abstract presented at ANESTHESIOLOGY 2021 recommended use of noninvasive, continuous Masimo PVi® to guide fluid administration during oncosurgery.

New Study Recommends the Use of Masimo PVi® to Guide Fluid Administration During Major Oncosurgery with Lung Ultrasonography

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release third quarter 2021 financial results for the period ended October 2, 2021, after the market closes on Tuesday, October 26, 2021. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please u

Masimo to Report Third Quarter 2021 Financial Results After Market Close on Tuesday, October 26

Masimo's (MASI) EMMA is likely to aid in maintaining an optimal range of PaCO2 in preterm infants undergoing mechanical ventilation in the neonatal intensive care unit.

Masimo's (MASI) EMMA Capnography on Neonates Favored by New Study

TOKYO--(BUSINESS WIRE)--A new study found that the Masimo EMMA® Portable Capnograph "may be considered an effective monitoring device" for mechanically ventilated neonates.

New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Founder and CEO Joe Kiani has been appointed to President Biden's Council of Advisors on Science and Technology.

Masimo CEO Joe Kiani Appointed to President's Council of Advisors on Science and Technology

Edwards Lifesciences

Graco

Lululemon Athletica

USANA Health Sciences

According to the “Good Companies Screen,” one of several Premium screens under the All-in-One Screener, five stocks with high financial strength and profitability are Edwards Lifesciences Corp. ( EW , Financial), Lululemon Athletica Inc. ( LULU , Financial), Masimo Corp. ( MASI , Financial), Graco Inc. ( GGG , Financial) and Usana Health Sciences Inc. ( USNA , Financial).

5 Good Companies With High Profitability

Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.

Masimo (MASI) Launches SuperSensor, Boosts Product Profile

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo announces the CE marking & European launch of the single-patient-use rainbow® SuperSensor™, with 12 noninvasive parameters on a single sensor.

Masimo Launches Single-patient-use rainbow® SuperSensor™

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 4:15 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops an

Masimo to Present in Morgan Stanley 19th Annual Global Healthcare Conference

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.

News for Masimo Stock (MASI)